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Background:  α1-Antitrypsin (AAT) is the major serum serine-protease inhibitor. In the current study we tested the effects of exogenous human AAT 
on left ventricular remodeling and function after acute myocardial infarction (AMI) in the mouse.
Methods:  Adult male ICR mice were randomly assigned to treatment with AAT (2 mg, i.p) or saline in AMI induced by surgical coronary artery 
ligation for 30 minutes and reperfusion (N=6 per group). Transthoracic echocardiography was performed at baseline and 7 days after surgery for 
measuring of LV end-diastolic (LVEDD) and systolic (LVESD) diameters, and LV fractional shortening (LVFS). Infarct scar size was measured by 
pathological examination. Plasma levels of the monocyte chemoattractant protein-1 (MCP-1) were determined in additional groups of AAT- or saline-
treated mice 6 hours after AMI (N=4 per group).
Results:  After AMI, mice treated with AAT exhibited a 90% smaller increase in LVEDD, 55% smaller increase in LVESD, and 55% smaller decrease in 
LVFS (p<0.05 vs saline for all comparisons). There was a 47% smaller infarct scar in the LV in AAT-treated mice (p<0.05 vs Saline). MCP-1 levels were 
also significantly reduced in AAT-treated mice (79±30 vs 2±2 pg/ml, p<0.05 vs saline).
Conclusions:  Exogenous administration of AAT during AMI leads to preservation of viable myocardium and prevention of adverse cardiac 
remodeling
